Emanuele Bosi

EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics

A systematic literature review and meta‐analysis of real‐world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes

HOMA-IR and the Matsuda Index as predictors of progression to type 1 diabetes in autoantibody-positive relatives

Hydroxychloroquine in Stage 1 Type 1 Diabetes

Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

Ladarixin, an inhibitor of the interleukin‐8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp> , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

Advancing the global public health agenda for NAFLD: a consensus statement

Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI)

The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose: A prospective observational cohort study

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

International consensus on use of continuous glucose monitoring

International Consensus on Use of Continuous Glucose Monitoring

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

Identification of Novel Genetic Loci Associated with Thyroid Peroxidase Antibodies and Clinical Thyroid Disease

Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

Glucose variability: An emerging target for the treatment of diabetes mellitus

Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes